Last reviewed · How we verify

glargine and humalog

Riverside University Health System Medical Center · FDA-approved active Small molecule

Glargine is a long-acting basal insulin that provides steady glucose control, while Humalog is a rapid-acting insulin that covers mealtime glucose spikes.

Glargine is a long-acting basal insulin that provides steady glucose control, while Humalog is a rapid-acting insulin that covers mealtime glucose spikes. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.

At a glance

Generic nameglargine and humalog
SponsorRiverside University Health System Medical Center
Drug classInsulin analog combination (basal-bolus therapy)
TargetInsulin receptor
ModalitySmall molecule
Therapeutic areaDiabetes
PhaseFDA-approved

Mechanism of action

Glargine (insulin glargine) is a long-acting insulin analog that binds to insulin receptors to promote glucose uptake and storage, providing basal insulin coverage over 24 hours. Humalog (insulin lispro) is a rapid-acting insulin analog that quickly lowers postprandial (after-meal) blood glucose by enhancing cellular glucose uptake. Together, they mimic physiologic insulin secretion with basal-bolus dosing.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: